Oslo University Hospital, Spesialsykehuset for epilepsi
Oslo, 4950 Nydalen, Norway
NCT Number: NCT04264780
This study will give important information about long term consequences of temporal lobe epilepsy surgery on cognition (memory, language, concentration etc), psychiatric function and quality of life.
Looking for future studies?
Notify Me30 year and older
All sexes
Observational
Oslo, 4950 Nydalen, Norway
All patients in Norway who have undergone temporal lobe epilepsy surgery ten years ago or more, will be invited to participate. Two groups will be compared: patients who are younger than 50 years of age vs patients who are older than 50 years of age.
The aim of the study is to improve preoperative information to future epilepsy surgery patients, to aid medical personnel (doctors, psychologists) in the selection of patients for surgery, and to improve knowledge of need for long term follow-up and rehabilitation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Neuropsychological follow-up examination, including questionaires
Other names: MRI scan
Time frame: During single data collection session, aproximately 2 hours
Memory will be measured by Rey Auditory Verbal Learning Test, results reported as raw scores from 1-worst to 15-best; and Diagnosticum für Cerebralschädugung-Revised - DCS-R, results reported as raw scores from 1-worst to 15-best. All results will be converted to T-scores with average 50, standard deviation 10.
Time frame: During single data collection session, aproximately 2 hours
Language will be measured by the subtest "Similarities" from Wechsler Adult Intelligence Scale - WAIS-III, results reported as raw scores from 1-worst to 33-best; Boston Naming Test-results reported as raw scores from 1-worst to 60-best; Letter Fluency from Delis Kaplan Executive Function Scale-D-KEFS, raw scores from 1-worst and up. All results will be converted to T-scores.
Time frame: During single data collection session, aproximately 2 hours
Visuospatial abilities will be measured by the subtest "Block Design" from WAIS-III, raw scores from 1-worst to 68-best. Results will be converted to T-scores.
Time frame: During single data collection session, aproximately 2 hours
Executive function will be measured by the subtest "Digit Span" from WAIS-III, raw scores from 1-worst, to 30-best; Trails A and B from Halstead test battery, raw scores from 1-worst and up. All results will be converted to T-scores.
Time frame: During single data collection session, aproximately 2 hours
Beck Depression Inventory (raw scores divided in 4 categories: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression and 29-63 serious depression).
Time frame: During single data collection session, aproximately 2 hours
Beck Anxiety Inventory (raw scores divided in 4 categories: 0-7 minimal anxiety, 8-15 mild anxiety, 16-25 moderate anxiety and 26-63 serious anxiety).
Time frame: During single data collection session, aproximately 2 hours
Quality of Life in Epilepsy - QUOLIE 89 - results will be reported as overall score ranging from 26-worst, to 95-best, and converted to T-score with average 50, standard deviation 10)
Oslo University Hospital
Other
Epilepsy Surgery and Cognition, Psychiatric Function and Quality of Life - Outcome 10 Years or More After Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04897776
Brain Diseases, Central Nervous System Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT00931619
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT00706160
Behavior, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03265925
Brain Diseases, Central Nervous System Diseases
Chicago, Illinois, United States
View Trial Details